Alopecia totalis
diseaseOn this page
Summary
Alopecia totalis (MONDO:0019080) is a disease and 21 clinical trials. Top therapeutic interventions include tofacitinib, abatacept, and cyclosporine. A subtype of alopecia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe)
- Phenotypes (HPO): 10
- Clinical trials: 21
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 10.5 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
10 HPO clinical features (Orphanet curated; top 10 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002293 | Alopecia of scalp | Very frequent (80-99%) |
| HP:0007418 | Alopecia totalis | Very frequent (80-99%) |
| HP:0001045 | Vitiligo | Occasional (5-29%) |
| HP:0001803 | Nail pits | Occasional (5-29%) |
| HP:0001806 | Onycholysis | Occasional (5-29%) |
| HP:0001808 | Fragile nails | Occasional (5-29%) |
| HP:0002037 | Inflammation of the large intestine | Occasional (5-29%) |
| HP:0002960 | Autoimmunity | Occasional (5-29%) |
| HP:0030804 | Trachyonychia | Occasional (5-29%) |
| HP:0100651 | Type I diabetes mellitus | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | alopecia totalis |
| Mondo ID | MONDO:0019080 |
| Orphanet | 700 |
| ICD-11 | 1633035058 |
| SNOMED CT | 19754005 |
| UMLS | C0263504 |
| MedGen | 75525 |
| GARD | 0000613 |
| MedDRA | 10001766 |
| Is cancer (heuristic) | no |
Also known as: alopecia totalis
Disease family
This is a subtype of alopecia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hair anomaly › alopecia › alopecia totalis
Related subtypes (25): alopecia, isolated, telogen effluvium, alopecia areata, chemotherapy-induced alopecia, alopecia mucinosa, atrichia with papular lesions, loose anagen syndrome, Satoyoshi syndrome, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, hereditary hypotrichosis with recurrent skin vesicles, alopecia antibody deficiency, pseudopelade of Brocq, frontal fibrosing alopecia, Quinquaud’s folliculitis decalvans, Graham Little-Piccardi-Lassueur syndrome, lichen planopilaris, hypotrichosis simplex, hypotrichosis simplex of the scalp, endocrine alopecia, alopecia universalis onychodystrophy vitiligo, central centrifugal cicatricial alopecia, ectodermal dysplasia alopecia preaxial polydactyly, Slti-Salem syndrome, microcephaly sparse hair intellectual disability seizures, alopecia universalis
Subtypes (2): alopecia, congenital, alopecia areata 2
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| Not specified | 5 |
| PHASE4 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07381556 | PHASE4 | RECRUITING | Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study |
| NCT07406204 | PHASE4 | NOT_YET_RECRUITING | Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) |
| NCT01167946 | PHASE4 | COMPLETED | Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata |
| NCT06278402 | PHASE3 | COMPLETED | Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. |
| NCT06747611 | PHASE2 | RECRUITING | Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata |
| NCT00746980 | PHASE2 | WITHDRAWN | Efalizumab in the Treatment of Alopecia, Phase II |
| NCT01314495 | PHASE2 | WITHDRAWN | Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis |
| NCT02197455 | PHASE2 | COMPLETED | Tofacitnib for the Treatment of Alopecia Areata and Variants |
| NCT02812342 | PHASE2 | COMPLETED | Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants |
| NCT03315689 | PHASE2 | COMPLETED | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) |
| NCT03532958 | PHASE2 | WITHDRAWN | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata |
| NCT03551821 | PHASE2 | COMPLETED | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata |
| NCT03759340 | PHASE2 | TERMINATED | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) |
| NCT04011748 | PHASE2 | UNKNOWN | Clinical Application of Stem Cell Educator Therapy in Alopecia Areata |
| NCT04238091 | PHASE2 | WITHDRAWN | Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata |
| NCT05589610 | PHASE2 | COMPLETED | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata |
| NCT00069589 | Not specified | ACTIVE_NOT_RECRUITING | Alopecia Areata Registry |
| NCT06283316 | Not specified | RECRUITING | Systemic Treatments for Alopecia Areata Registry |
| NCT02312882 | Not specified | COMPLETED | Tofacitinib for the Treatment of Alopecia Areata and Its Variants |
| NCT05098600 | Not specified | COMPLETED | The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic |
| NCT07101471 | Not specified | COMPLETED | Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TOFACITINIB | 4 | 8 |
| ABATACEPT | 4 | 1 |
| CYCLOSPORINE | 4 | 1 |
| EFALIZUMAB | 4 | 1 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | 4 | 1 |
| IFIDANCITINIB | 2 | 2 |
Related Atlas pages
- Drugs: Tofacitinib, Abatacept, Cyclosporine, Efalizumab, Methylprednisolone